These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30185936)

  • 1. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia.
    Moon HW; Yang JH; Choi JB; Bae WJ; Cho HJ; Hong SH; Lee JY; Kim SW; Park SH; Han K; Ha US
    Sci Rep; 2018 Sep; 8(1):13223. PubMed ID: 30185936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database.
    Lee JW; Kim JH
    J Korean Med Sci; 2022 Mar; 37(12):e95. PubMed ID: 35347903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
    Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
    J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
    Zabkowski T; Saracyn M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
    Barkin J; Diles D; Franks B; Berner T
    Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
    Kawabe K
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the veterans affairs health system.
    Burk M; Furmaga E; Dong D; Cunningham F
    J Manag Care Pharm; 2004; 10(5):423-32. PubMed ID: 15369425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery.
    Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM
    Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
    Nickel JC
    Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study.
    Park J; Lee YJ; Lee JW; Yoo TK; Chung JI; Yun SJ; Hong JH; Seo SI; Cho SY; Son H
    Korean J Urol; 2015 Mar; 56(3):233-9. PubMed ID: 25763128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery.
    Bell CM; Hatch WV; Fischer HD; Cernat G; Paterson JM; Gruneir A; Gill SS; Bronskill SE; Anderson GM; Rochon PA
    JAMA; 2009 May; 301(19):1991-6. PubMed ID: 19454637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia].
    Lee J; Choi NK; Jung SY; Kim YJ; Seong JM; Oh SJ; Park BJ
    J Prev Med Public Health; 2009 May; 42(3):165-70. PubMed ID: 19491559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.